ClinicalTrials.gg

Program

intismeran autogene

Also written as “Intismeran autogene”, “mRNA-4157” and “Intismeran”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Renal Cell · Carcinoma, Squamous Cell, led by 2 companies.

Furthest: phase 3, since Jun 27, 202312 company-led studies, 11 open or runningCo-development: Moderna and Merck, Oct 2022Next primary completion: Apr 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck109 open or runningphase 3since Jun 27, 2023Jun 27, 2023Apr 23, 2027phase 2 · NCT06305767
Moderna22 open or runningphase 2since Mar 29, 2019Oct 13, 2017Nov 21, 2027phase 1 · NCT03313778
  • Named in Merck’s own pipeline as intismeran autogene (V940), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2017First study: phase 1 study in Solid TumorsNew to ModernaModerna · NCT03313778 · 161 enrolled · United States, Australia, Japan and more
  2. Mar 29, 2019Phase 2 study in MelanomaModerna · NCT03897881 · 267 enrolled · United States, Australia
  3. Oct 12, 2022Merck develops it with ModernaCo-developmentWorldwide, costs and profits shared equally · announced · Merck
  4. Jun 27, 2023Merck's first study: phase 3 study in MelanomaNew to MerckMerck · NCT05933577 · 1,089 enrolled · United States, Argentina, Australia and more
  5. Oct 5, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT06077760 · 868 enrolled · United States, Argentina, Australia and more
  6. Feb 29, 2024Phase 3 study in Carcinoma, Squamous CellMerck · NCT06295809 · 46 enrolled · United States, Argentina, Australia and more
  7. Mar 5, 20242 phase 2 studiesMerck · NCT06305767, NCT06307431
  8. Sep 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT06623422 · 680 planned · United States, Argentina, Australia and more
  9. Feb 4, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06833073 · 308 planned · United States, Argentina, Australia and more
  10. Apr 29, 2025Phase 2 study in MelanomaMerck · NCT06961006 · 160 enrolled · United States, Australia, Canada and more
  11. Oct 24, 2025Phase 2 study in Squamous Non-small Cell Lung CancerMerck · NCT07221474 · 180 planned · United States, Argentina, Australia and more
  12. Apr 1, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT07513376 · 876 planned · United States, Australia, Brazil and more

Ahead

  1. Apr 23, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06305767
  2. Nov 21, 2027Primary completion: phase 1 study in Solid TumorsModerna · NCT03313778
  3. Jan 8, 2028Primary completion: phase 2 study in Carcinoma, Renal CellMerck · NCT06307431
  4. Jul 22, 2028Primary completion: phase 2 study in MelanomaMerck · NCT06961006

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities.…”NCIt, read by Claude

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07513376Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3RecruitingMerckAug 22, 2034876
NCT07221474Squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more2RecruitingMerckJul 2, 2029180
NCT06961006Melanoma · United States, Australia, Canada and more2Active, not recruitingMerckJul 22, 2028160
NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more2RecruitingMerckSep 3, 2031308
NCT06623422Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingMerckMay 16, 2033680
NCT06307431Carcinoma, Renal Cell · United States, Argentina, Australia and more2Active, not recruitingMerckJan 8, 2028272
NCT06305767Urinary Bladder Neoplasms · United States, Australia, Canada and more2Active, not recruitingMerckApr 23, 2027230
NCT06295809Carcinoma, Squamous Cell · United States, Argentina, Australia and more3TerminatedMerckMar 5, 202646
NCT06077760Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMerckJun 25, 2030868
NCT05933577Melanoma · United States, Argentina, Australia and more3Active, not recruitingMerckOct 26, 20291,089
NCT03897881Melanoma · United States, Australia2Active, not recruitingModernaNov 21, 2032267
NCT03313778Solid Tumors · United States, Australia, Japan and more1Active, not recruitingModernaNov 21, 2027161

How it is read

Names in the registry

  • “Intismeran autogene”, 8 entries
  • “mRNA-4157”, 2 entries
  • “Intismeran”, 1 entry
  • “Intismeran Autogene”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.